Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) - Total Assets
Based on the latest financial reports, Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) holds total assets worth TL2.15 Billion TRY (≈ $48.07 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ANGEN operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret - Total Assets Trend (2018–2024)
This chart illustrates how Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's total assets have evolved over time, based on quarterly financial data. See Anatolia Tani ve Biyoteknoloji Urunleri net assets for net asset value and shareholders' equity analysis.
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret - Asset Composition Analysis
Current Asset Composition (December 2024)
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's total assets of TL2.15 Billion consist of 42.4% current assets and 57.6% non-current assets.
| Asset Category | Amount (TRY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | TL0.00 | 11.5% |
| Accounts Receivable | TL107.38 Million | 6.0% |
| Inventory | TL360.98 Million | 20.2% |
| Property, Plant & Equipment | TL0.00 | 0.0% |
| Intangible Assets | TL380.41 Million | 21.3% |
| Goodwill | TL0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ANGEN stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's current assets represent 42.4% of total assets in 2024, a decrease from 50.9% in 2018.
- Cash Position: Cash and equivalents constituted 11.5% of total assets in 2024, up from 4.7% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, a decrease from 23.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 21.3% of total assets.
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret Competitors by Total Assets
Key competitors of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
|
China | CN¥2.00 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Vitrolife AB
ST:VITR
|
Sweden | Skr11.24 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.71 | 10.33 | 25.28 |
| Quick Ratio | 2.09 | 6.08 | 22.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | TL521.60 Million | TL682.02 Million | TL680.03 Million |
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret - Advanced Valuation Insights
This section examines the relationship between Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.52 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -8.5% |
| Total Assets | TL1.79 Billion |
| Market Capitalization | $45.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret's assets decreased by 8.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (2018–2024)
The table below shows the annual total assets of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | TL1.79 Billion ≈ $40.02 Million |
-8.54% |
| 2023-12-31 | TL1.95 Billion ≈ $43.76 Million |
+127.99% |
| 2022-12-31 | TL856.92 Million ≈ $19.19 Million |
-0.33% |
| 2021-12-31 | TL859.77 Million ≈ $19.26 Million |
+117.25% |
| 2020-12-31 | TL395.76 Million ≈ $8.86 Million |
+1057.63% |
| 2019-12-31 | TL34.19 Million ≈ $765.70K |
+72.88% |
| 2018-12-31 | TL19.77 Million ≈ $442.91K |
-- |
About Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret
Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S., a biotechnology company, engages in the design, development, and manufacture of real-time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments in Turkey. It offers microbiology, genetic disorder, panel, sequencing, and food testing kits; and manual spin column and magnetic bead nucleic acid ext… Read more